Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
High Plains Journal12d
Company unveils product to help band castration in calves
Solvet, of Alberta, Canada, the maker of Lidoband that addresses the pain and discomfort associated with band castration in ...
Tharimmune announce preclinical TH023 results
Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized ...